Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
RVMD 11.27.2024
About Gravity Analytica
Recent News
- 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
- 01.06.2025 - Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
- 12.05.2024 - Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Recent Filings
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.
The webcast will take place at 8:00 a.m. Eastern Time on Monday, December 2, 2024. To access the webcast, clickhere. An archived replay will be available on the “Events & Presentations” page of the Revolution Medicines website athttps://ir.revmed.com/events-and-presentationsfor at least 14 days following the live event.
About Revolution Medicines, Inc.Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.
Media & Investor Contacts: media@revmed.com investors@revmed.com